Jon Saxe

Mr. Saxe joined the Board in September 2002. From January 1995 to May 1999, he was President of Protein Design Labs (now PDL BioPharma) and continues to serve as a director. In 1999 he was also an Executive-in-Residence at Institutional Venture Partners, a venture capital firm. In addition, Mr. Saxe is a Director of Durect, First Horizon Pharmaceuticals, InSite Vision, Questcor Pharmaceuticals, and SciClone Pharmaceuticals and is Chairperson or a Director of several private companies, including Astex Therapeutics in Cambridge, UK. Mr. Saxe served as President of Saxe Associates, a biotechnology and pharmaceutical consulting firm, from May 1993 to December 1994. He served as President, Chief Executive Officer, and as a Director of Synergen (acquired by Amgen), a biopharmaceutical company, from 1989 to 1993. From 1984 until 1989, Mr. Saxe was Vice President, Licensing and Corporate Development at Hoffmann-LaRoche and Head of Patent Law at the company from 1978 until 1989. Mr. Saxe received his B.S. in Chemical Engineering from Carnegie-Mellon University, a J.D. from George Washington University School of Law, and his LL.M. from New York University School of Law.